Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-02
2006-05-02
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S146000
Reexamination Certificate
active
07037924
ABSTRACT:
Compounds of formula (I) are provided,wherein R1and R2are as designated in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.
REFERENCES:
patent: 4042697 (1977-08-01), Garside et al.
patent: 2.199.462 (1974-04-01), None
patent: 63-310813 (1988-12-01), None
patent: WO 01/55117 (2001-08-01), None
Postaire et al, Bulletin de la Societe Chimique de France, vol. 6, p. 982-8, 1988.
S.L. Bearne, J. Biol. Chem.., 271 (1996) 3052-3057.
M.A. Badet-Denisot, et. al., Bioorg. Med. Chem. Letters, 5, (1995) 815-820.
S.L. Bearne, et. al., Biochem., 34, (1995) 11515-11520.
F. Massiere, et. al., J. Amer. Chem. Soc., 119 (1997) 5748-5749.
H. Chmara, J. Gen. Microbiol., 131, (1985) 265-271.
S. Milewski, et. al., Biochim. Biophys. Acta, 1115 (1992) 225-229.
E. Anselmi, et. al., J. Pharm. Pharmacol (1992) 44(4), 337-43.
F. Markwardt, et. al., Acta Biologica et Medica Germanica (1969) 23(2), 295-306.
Chen Chen, et. al., J. Med. Chem. (2001) 44, 4001-4010.
F. Bister-Miel, et. al., Plantes Medicinales et Phytotherapie (1986), Tome XX, n° 1, p. 3-7.
E. Postaire, et. al., Ann. Pharmaceutiques Francaises (1985) 43, N°6, pp. 547-556.
D. Walterova, et . al., Collection Czechoslov. Chem. Commun, (1980), 45, pp. 956-965.
E. Taborska, et. al., Fumaflorine, a new 1-benzylisoquinoline alkaloid fromFumaria densiflora; Heterocycles (1997), 45(4), 817-821.
E. Taborska, et. al.,Fumaria densifloraDC alkaloids; Collection of Czechoslovak Chemical Communications (1996) 61(7), 1064-1072.
E. Postaire, et. al., Vanadic oxidation of papaverine in 2.5M and 5M sulfuric acid; Bulletin de la Societe Chimique de France (1988) (6), 982-8.
M. Redrup, Analysis of the degradation products of diproteverine by moving belt LC/MS; Organic Mass Spectrometry (1989), 24(5), 309-16.
H. Ansel, et. al., Pharmaceutical Dosage Forms and Drug Delivery (6thEd. 1995) p. 108-109.
Krogsgaard-Larsen, et. al., Textbook of Drug Design and Development (2d Ed. 1996) p. 152-191.
Bolin David Robert
Chen Shaoqing
Mischke Steven Gregory
Qian Yimin
Davis Zinna N.
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Tramaloni Dennis P.
LandOfFree
Glutamine fructose-y-phosphate amidotransferase (GFAT)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glutamine fructose-y-phosphate amidotransferase (GFAT)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glutamine fructose-y-phosphate amidotransferase (GFAT)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3552379